Q-omics provides the consensus-scored MRPL32 profile across patient tissues and cancer cell-line models. MRPL32 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MRPL32 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, MRPL32 protein abundance shows 20,296 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, BLCA, and LSCC as cancer lineages where MRPL32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL32 survival associations across molecular data types. MRPL32 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL32 RNA expression–survival associations across cancer types. High MRPL32 expression shows unfavorable associations in HNSC, LGG, LUAD, UVM and KICH, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MRPL32 RNA expression.
This table summarizes MRPL32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL32 shows lower tumor expression in THCA and higher tumor expression in BLCA, HNSC, STAD, COAD and LUAD. The BLCA box plot shows higher MRPL32 RNA expression in tumor versus normal tissue (log2 FC = +0.525, t-test p < 0.001).
This table shows molecular features associated with MRPL32 in patient tissues and cancer cell lines. In patient samples, MRPL32 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL32 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
